Lemaitre Vascular (LMAT) Common Equity (2010 - 2026)

Lemaitre Vascular (LMAT) has 17 years of Common Equity data on file, last reported at $406.6 million in Q1 2026.

• On a quarterly basis, Common Equity rose 16.99% year-over-year to $406.6 million in Q1 2026; TTM through Mar 2026 was $406.6 million, a 16.99% increase from a year earlier, with the FY2025 full-year figure at $393.5 million, up 16.67% from the prior year.
• Common Equity for Q1 2026 stood at $406.6 million, up from $393.5 million in the prior quarter.
• Over the last five years, Common Equity for LMAT reached as high as $406.6 million in Q1 2026 and fell as low as $257.8 million in Q1 2022.
• Historically, Common Equity has averaged $316.2 million across 5 years, with a median of $308.5 million in 2024.
• On a YoY basis, Common Equity climbed as much as 45.21% in 2022 and fell as far as 4.9% in 2022.
• Year by year, Common Equity stood at $268.2 million in 2022, then rose by 11.07% to $297.9 million in 2023, then rose by 13.22% to $337.3 million in 2024, then rose by 16.67% to $393.5 million in 2025, then grew by 3.33% to $406.6 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $406.6 million in Q1 2026, $393.5 million in Q4 2025, and $378.9 million in Q3 2025.